Tests a ketone drink for heart health in women with polycystic ovary syndrome
Tests a ketone drink against a placebo in women with polycystic ovary syndrome.
Plain-language title generated from the registry record
Registry title: Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome
Key facts
- Where
- Montreal, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for females aged 18 to 40, with and without polycystic ovary syndrome (PCOS). Participants drink a ketone supplement and a placebo drink on two different days.
- Age
- 18 to 40 years
- Sex
- Females only (female sex assigned at birth)
- Disease stage
- PCOS diagnosis for the PCOS group; a control group of similar age and body mass index.
- Earlier treatment
- Cannot currently use medicines that may affect the results, such as anti-hypertensives, anti-androgens or metformin.
Main reasons for not taking part
- Current smoker or long history of smoking
- Current or past overt cardiometabolic disease (such as stage 2 hypertension, diabetes, heart disease), neurologic disease or endocrine disorder (other than PCOS)
- Currently pregnant or breastfeeding
- Current use of medicines that may affect the results (such as anti-hypertensives, anti-androgens, metformin)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06155708, who can take part
Where in Canada
- Cardiovascular Health and Autonomic Research LaboratoryMontreal, CanadaContact: Charlotte Usselman, Ph.DTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- McGill University
- Trial code
- NCT06155708
- Record updated
- 22 January 2025
- Original description
Polycystic ovary syndrome (PCOS) affects 1 in 5 females of reproductive age. Commonly characterized as a disorder of infertility, PCOS is often accompanied by 3 potent cardiovascular disease (CVD) risk factors: insulin resistance, endothelial dysfunction, and elevated blood pressure. Accordingly, PCOS is associated with the development of CVD, the second leading cause of death in females in Canada. However, effective treatments to improve cardiovascular health in PCOS are lacking.Read full original descriptionShow less
Exogenous Ketone Supplementation to Improve Cardiovascular Disease Risk Factors in Females with Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 1 in 5 females of reproductive age. Commonly characterized as a disorder of infertility, PCOS is often accompanied by 3 potent cardiovascular disease (CVD) risk factors: insulin resistance, endothelial dysfunction, and elevated blood pressure. Accordingly, PCOS is associated with the development of CVD, the second leading cause of death in females in Canada. However, effective treatments to improve cardiovascular health in PCOS are lacking.
Exogenous ketone monoester (KME) ingestion has been shown to improves outcomes associated with insulin resistance, endothelial function, and blood pressure regulation in healthy individuals and individuals predisposed to CVD. Therefore, oral ketone supplements offer a practical and effective strategy for improving cardiovascular health; however, this treatment has yet to be evaluated in PCOS.
Therefore, the overall goal of this project is to employ KME ingestion to improve markers of cardiovascular health in females with PCOS.
On two different days, participants will consume either a beverage containing a ketone supplement or a beverage containing a placebo supplement. The objectives are to compare responses between KME and placebo ingestion, and examine all outcomes related to cardiovascular health in females with PCOS in comparison with female controls of similar age and body mass index. The effects of KME ingestion will be quantified on: 1) glycemic control during an oral glucose tolerance test; 2) endothelial function using the flow-mediated dilation test; 3) blood pressure and acute blood pressure regulation; and 4) hemodynamic responses to acute exercise.
Inclusion: All female participants will report female sex assigned at birth; All participants will be aged 18 to 40; PCOS diagnosis.
Exclusion: Current use of medications which may affect our outcomes of interest (e.g., anti-hypertensives, anti-androgens, metformin); Current smokers or a prolonged history of smoking; Presence or history of overt cardiometabolic disease (e.g., stage 2 hypertension, diabetes, heart disease), neurologic disease, or endocrinopathy (with the exception of PCOS); Current pregnancy or currently breastfeeding.